Edwards Lifesciences Corporatio (EW)

Edwards Lifesciences Corporatio's Q·Score is 6.8/10 (Neutral), reflecting its current fundamentals, analyst data, and valuation metrics. Clean balance sheet with low leverage (0.1× debt-to-equity). Key area to monitor: earnings contracting 25% year-over-year. This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.

The consensus price target for EW is $100.96, based on ratings from 26 Wall Street analysts. This is 17.3% above the current price of $86.07. Price targets are forward-looking estimates and not guarantees of future performance.

Edwards Lifesciences Corporatio (EW) scores favorably on valuation metrics relative to sector peers and analyst targets. Its forward P/E ratio stands at 25.5×. The consensus analyst price target of $100.96 is 17% above the current price.

Edwards Lifesciences Corporatio's next earnings report is expected on approximately October 29, 2026.

Edwards Lifesciences Corporatio has a net profit margin of 15.4%, which is solid for most industries. Its gross margin stands at 77.8%, indicating a high-margin business model.

Edwards Lifesciences Corporatio is reporting solid revenue growth of 13.6% year-over-year. However, earnings declined 25.4%, which warrants monitoring.

Edwards Lifesciences Corporatio has a debt-to-equity ratio of 0.07×, reflecting a very low debt-to-equity ratio, signalling a conservatively financed balance sheet.